- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00109512
Endometriosis Trial: Study of NBI-56418 in Endometriosis
February 21, 2012 updated by: Abbott
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of NBI-56418 in Endometriosis
This is a Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study with subjects randomized to one of three treatment groups, placebo, 75 mg and 150 mg in a 1:1:1 ratio.
Study drug was administered once daily for 12 weeks.
After the last dose at the end of Week 12, follow-up continued every 4 weeks for 12 weeks.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
76
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85032
- Site Reference ID/Investigator# 56266
-
-
California
-
San Diego, California, United States, 92103
- Site Reference ID/Investigator# 55210
-
San Ramon, California, United States, 94566
- Site Reference ID/Investigator# 55214
-
-
Florida
-
Clearwater, Florida, United States, 33759
- Site Reference ID/Investigator# 56267
-
-
Illinois
-
Champaign, Illinois, United States, 61820
- Site Reference ID/Investigator# 56270
-
Chicago, Illinois, United States, 60612
- Site Reference ID/Investigator# 56273
-
Oak Brook, Illinois, United States, 60523
- Site Reference ID/Investigator# 56269
-
Peoria, Illinois, United States, 61615
- Site Reference ID/Investigator# 56271
-
-
Kentucky
-
Louisville, Kentucky, United States, 40291
- Site Reference ID/Investigator# 56272
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27103
- Site Reference ID/Investigator# 55213
-
-
Texas
-
Arlington, Texas, United States, 76012
- Site Reference ID/Investigator# 55211
-
-
Utah
-
Sandy, Utah, United States, 84070
- Site Reference ID/Investigator# 56268
-
-
Virginia
-
Richmond, Virginia, United States, 23294
- Site Reference ID/Investigator# 56274
-
Virginia Beach, Virginia, United States, 23451
- Site Reference ID/Investigator# 55212
-
-
Washington
-
Spokane, Washington, United States, 99204
- Site Reference ID/Investigator# 56275
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 49 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria
- Be female, aged 18 to 49 years, inclusive.
- Have pelvic pain and dysmenorrhea resulting in a Composite Pelvic Sign and Symptoms Score (CPSSS) of ≥ 6.
- Have had a diagnosis of endometriosis made following laparoscopic visualization of the disease within the last 5 years of the start of screening.
- Have regular menstrual cycles (28 days ±5 days) for greater than or equal to 2 years. For the cycle that immediately precedes dosing, cycle length will be determined as part of the medical history.
- Have a Body Mass Index between 18 and 30 kg/m2.
- Agree to use two forms of non-hormonal contraception (unless sterilized by tubal ligation) for greater than or equal to 3 months prior to Screening through ovulation and return of menses after treatment.
- Have a negative serum pregnancy test at Screening and a negative urine pregnancy test at prior to dosing at the beginning of Week 1.
- Have a cervical smear negative for malignancy at Screening.
- Be willing to comply with all study procedures and restrictions.
- Be able to read, understand, and sign the ICF (informed consent form) before entering into the study.
- Be willing to provide authorization for access to personal health information in conjunction with US Health Insurance Portability and Accountability Act (HIPAA).
Exclusion Criteria
- Are currently receiving a GnRH agonist or GnRH antagonist, or have received any of these agents within 6 months of Screening.
- Have been nonresponsive to GnRH agonist or antagonist therapy for the management of endometriosis.
- Are currently receiving hormonal therapy including the oral contraceptive pill or have received any of these agents within 3 months of Screening.
- Are on any concurrent medical treatment/medications or have had surgical or hormonal treatment other than oral contraceptives for endometriosis within 3 months of Screening.
- Have uterine fibroids or any other pelvic lesions greater than or equal to 3 cm in diameter as verified by ultrasound.
- Are currently breast-feeding an infant.
- Are using any steroid preparation, taken by any route (e.g., oral, inhaled) on a chronic or regular basis within 3 months of Screening.
- Have an unstable medical condition or chronic disease (including history of neurological [including cognitive], hepatic, renal, cardiovascular, gastrointestinal, pulmonary, or endocrine disease), or malignancy that could confound interpretation of the study outcomes.
- Have chronic pelvic pain that is not caused by endometriosis.
- Have any psychological disorder according to criteria indicated in the Diagnostics and Statistical Manual of Mental Disorders, 4th edition within one year before screening. Such disorders include, but are not limited to, alcohol and substance abuse/dependence.
- Have a history of poor compliance in clinical research studies.
- Have a medically significant illness in the 30 days before the beginning of Week 1.
- Have a medically significant abnormality observed upon Screening or the beginning of Week 1 physical examination, or in any other baseline measurement. Findings outside the standard reference ranges will be jointly approved with NBI's (Neurocrine Biosciences) Medical Monitor before being considered eligible for the study.
- Are using any investigational drug within 2 months of Screening.
- Have a positive human immunodeficiency virus antibody (HIV Ab), hepatitis B surface antigen (HBsAg), or hepatitis C virus antibody (HCV-Ab) assay at Screening or have a history of a positive result.
- Have an allergy, hypersensitivity, or intolerance to a GnRH agonist or antagonist.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: placebo
|
|
Experimental: NBI-56418 75 mg
|
|
Experimental: NBI-56418 150 mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total Composite Pelvic Signs and Symptom Scale (CPSSS) scores
Time Frame: Every 4 weeks
|
This scale is used to assess the signs (pelvic tenderness and induration) and symptoms (nonmenstrual pelvic pain, dysmenorrhea and dyspareunia) associated with endometriosis.
|
Every 4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Endometriosis Health Profile-5 (EHP-5)
Time Frame: Every 4 weeks
|
The EHP-5 assesses quality of life.
|
Every 4 weeks
|
Visual Analog Scale (VAS) scores
Time Frame: Every 4 weeks
|
VAS measures endometriosis pain.
|
Every 4 weeks
|
Number of Subjects with Adverse Events
Time Frame: Up to 24 weeks
|
Up to 24 weeks
|
|
Clinical Laboratory Tests
Time Frame: Up to 24 weeks
|
Up to 24 weeks
|
|
Vital Sign Measurements
Time Frame: Up to 24 weeks
|
Up to 24 weeks
|
|
Physical Examinations
Time Frame: Up to 24 weeks
|
Up to 24 weeks
|
|
Electrocardiogram (ECG) tracings
Time Frame: Up to 24 weeks
|
Up to 24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Laura Williams, MD, Abbott
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2005
Primary Completion (Actual)
June 1, 2006
Study Completion (Actual)
June 1, 2006
Study Registration Dates
First Submitted
April 28, 2005
First Submitted That Met QC Criteria
April 28, 2005
First Posted (Estimate)
April 29, 2005
Study Record Updates
Last Update Posted (Estimate)
February 22, 2012
Last Update Submitted That Met QC Criteria
February 21, 2012
Last Verified
February 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NBI-56418-0501
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Endometriosis
-
Fabio BarraCompletedEndometriosis | Endometriosis, Rectum | Endometriosis of Vagina | Endometriosis Rectovaginal Septum | Endometriosis Pelvic | Endometriosis of ColonItaly
-
Ospedale Policlinico San MartinoCompletedEndometriosis | Bowel Endometriosis | Endometriosis, Rectum | Endometriosis ColonItaly
-
BioGene Pharmaceutical Ltd.WithdrawnSafety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis (ELTA)Endometriosis | Endometriosis Ovary | Endometriosis, Rectum | Endometriosis ExternaSwitzerland
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...CompletedEndometriosis | Endometriosis-related Pain | Endometriosis Thoracic | Endometriosis of Lung | Endometriosis of PleuraItaly
-
Ospedale Policlinico San MartinoCompletedEndometriosis, Rectum | Endometriosis, SigmoidItaly
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaUnknownBowel Endometriosis | Endometriosis, RectumItaly
-
Ospedale Policlinico San MartinoActive, not recruitingEndometriosis, Rectum | Endometriosis of ColonItaly
-
Catholic University of the Sacred HeartCompletedPelvic Endometriosis | Endometriosis Outside PelvisItaly
-
Semmelweis UniversityUniversity of PecsNot yet recruitingEndometriosis | Endometriosis Ovary | Endometriosis Rectovaginal Septum
-
Catholic University of the Sacred HeartCompletedPelvic Endometriosis | Endometriosis Outside PelvisItaly
Clinical Trials on placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States